Fever-Tree shares rise amid Molson Coors deal talks

Fever-Tree’s share price dropped by 6% on Thursday after its first-half results revealed modest but steady progress, failing to excite investors despite improvements in its US market push and UK recovery.

Revenue climbed 8% to £183.6 million for the half ending June 30, 2026—the first UK growth in three and a half years. The company’s earnings before interest, taxes, and depreciation also rose 9% to £20.1 million, though observers called the gains incremental rather than transformative.

Barclays analyst Ashutosh Jain acknowledged the positive trend but said it fell short of projections, especially regarding the partnership with Molson Coors. The collaboration, which expanded distribution and marketing in the US, had been expected to generate stronger revenue growth. Jain said he had “expected a stronger uplift” from the Molson Coors tie-up, “given the significant increase in distribution reach, merchandising support and marketing investment.”

CEO Tim Warrillow said the business was well aware its US expansion “would take time,” but pointed to Circana data demonstrating accelerating sales growth in the country. Molson Coors has tens of thousands of salespeople and thousands of accounts to communicate with, and Warrillow noted the partnership’s progress would be an evolution rather than a revolution. The company reported accelerating US sales—6% growth in the first quarter, 11% in the second, and 16% in the third. Fever-Tree also increased its US market share by 2.5 percentage points, outperforming rivals.

The UK’s recovery, Warrillow noted, was not temporary but reflected a strategic shift away from tonic water. Non-tonic drinks, particularly ginger beer, surged 33% and now make up 47% of total sales. He said, “We’ve been busy diversifying our range away from tonic water for the last four to five years, and encouraging consumers to not just think of our products as mixers but drinks in their own right.”

US growth outpaces spirits decline

Analysts viewed the results with cautious hope. Panmure Liberum’s Anubhav Malhotra described the 11% US growth as significant, especially given the broader decline in US spirits sales. He pointed to the profit-sharing deal with Molson Coors, which could boost group EBITDA by 60% by 2028, a guaranteed upside for shareholders.

Read Also: Scottish price cap plan faces zero support

The stock’s decline suggests traders expect a slower pace than the company’s underlying performance suggests. While Fever-Tree’s US leadership and UK diversification provide stability, investors appear to want faster results from the Molson Coors alliance.

Similar premium drink brands expanding in the US often face the same challenge: distribution networks grow quickly, but sales take longer to materialize. The question now is whether Molson Coors’ resources will sustain volume increases, or if Fever-Tree’s development will remain gradual.

UK diversification proves strategic shift

For now, the results show advancement without a major leap. The test ahead is whether the partnership’s long-term rewards justify the current wait.

Fever-Tree’s UK recovery hinges on its ability to maintain momentum outside tonic water. The company’s shift toward standalone drinks, particularly ginger beer, now accounts for nearly half of sales. This diversification strategy, years in development, appears to be paying off as consumer preferences evolve.

Investors will watch closely whether the Molson Coors deal accelerates beyond its current trajectory. The partnership’s potential to lift EBITDA by 60% by 2028 remains a key factor, but the market’s reaction indicates patience may be wearing thin.